Sencure has developed an ultra-low-power biometric sensing chip and a library of signal-processing algorithms for medical monitoring and diagnostics, which it can license as IP. The chip targets wearable biometric solutions across cardiac monitoring, COPD, children’s asthma, neurological cases, EEG recordings, ICU-grade ventilation, vital-sign monitoring, COVID-19 symptom monitoring, athletic training/rehabilitation, and general stress/activity tracking. The technology reflects five years of R&D and is described by the company and investors as outperforming current medical chips on price and quality, with competitive advantages in much lower power consumption and smaller size. Sencure also develops textile-integrated medical wearables aimed at maximizing patient comfort in real-life monitoring situations. The company plans to use new financing to file patent applications, continue product development, and execute a global rollout. The financing round comprises a €1.0M investment from Cottonwood Technology Fund and €0.5M from co-investor Lumana Invest (totaling €1.5M). The article positions Sencure to participate in the growing medical-wearables market, which is projected to expand significantly by 2025. Sencure, based in Enschede, Netherlands, develops chips for medical wearable biosensors with a focus on remote patient monitoring. Its flagship SNCE-800 microprocessor is designed to capture high-quality electrophysiological signals such as ECG and EEG while consuming minimal power. The company says the chip enables smaller, more comfortable devices, extended battery life and faster medical-device development. Founded in 2021, Sencure originates from ItoM Medical BV, the 2018-founded medical branch of Semiconductor Ideas to the Market (ItoM) BV. Its products are used to measure a range of bioelectrical data including cardiac, respiratory and brain activity. Sencure says it will use the new funding to accelerate industrialisation of the SNCE-800 and bring biosensor solutions to market faster.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024